OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
Starting a new job	1142
New pathogen on the block	976
Inferring cancer metabolism from gene-expression data	906
Feeding latent brain metastasis	807
An inhospitable site	789
MYC inhibition, courtesy of E. coli	780
MDMX drives pre-leukaemia progression	740
CAF-induced physical constraints controlling T cell state and localization in solid tumours	588
Epigenetic remodelling drives fibroid development	565
Studying large genomic deletions with MACHETE	552
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	450
Cancer burden in low-income and middle-income countries	416
Computing brain metastasis impact	409
Breast milk for breast cancer detection	378
Hubs of transcriptional activity	340
To sleep, perchance to spread	331
Neutrophils: a roadblock for immunotherapy	328
Judith Campisi (1948–2024)	310
Linking pancreatic renewal and cancer initiation	307
Proximity labelling to study chromatin interactomes	250
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	248
The road less travelled	242
Digging for treasures in the tumour interactome	240
INVADEseq to study the intratumoural microbiota at host single-cell resolution	236
In vivo labelling system to study cell neighbourhoods	232

Obesity-induced neutrophil reprogramming	223
Quantum probes in cancer research	215
Tumour avatars to model patients’ responses to immunotherapy	206
Extrachromosomal DNA in cancer	206
Functional lineage tracing to study the clonal evolution of therapy resistance	205
Peto’s paradox put to the test	205
Revealing genomic secrets of archival FFPE samples	201
Investigating immune cells across time in vivo	193
Shining a light on tumour behaviour	191
Approaching cancer during pregnancy	188
Programming immune escape	186
Conventional chemotherapy: millions of cures, unresolved therapeutic index	183
The present and future of the Cancer Dependency Map	181
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	180
The metabolism of cancer cells during metastasis	175
Recent advances and discoveries in the mechanisms and functions of CAR T cells	166
Combinatorial strategies to target RAS-driven cancers	165
Characterization of the B cell receptor repertoire in melanoma	162
Creating a dietary vulnerability	161
Intercepting gastric cancer	157
Oncofetal reprogramming in tumour development and progression	155
Cancer proteogenomics: current impact and future prospects	150
Dissecting metastasis using preclinical models and methods	149
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	148
Tumour fatty acid metabolism in the context of therapy resistance and obesity	146
The language of chromatin modification in human cancers	144
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	130
Long noncoding RNAs in cancer metastasis	127
Polyamines in cancer: integrating organismal metabolism and antitumour immunity	127
Artificial intelligence in cancer research, diagnosis and therapy	120
Publisher Correction: Programmed death ligand 1 signals in cancer cells	120
Rational combination of cancer therapies with PD1 axis blockade	118
Emerging strategies to investigate the biology of early cancer	117
Defining and using immune archetypes to classify and treat cancer	115
Clonal expansion in non-cancer tissues	114
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	112
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	112
tRNA supply and demand	110
Impact of COVID-19 on in vivo work and patient sample availability for cancer research	109
Long-range gene regulation in hormone-dependent cancer	109
Cell states can give tumorigenesis a head start	107
Obesity as a promoter in BRCA mutation carriers	106
Lifestyle interventions for cancer survivors	97
Switching on cancer survival mechanisms	94
Lymphatic vessels in the age of cancer immunotherapy	93
Metabolic mechanisms of medulloblastoma metastasis	92
Reflecting on 20 years of progress	91
Bumps in the road lead to immunogenicity	89
Glutamylation is good for stability	88
Addressing systemic racism as the cancer of Black people: equity ethic-driven research	78

Towards cancer equity via patient outreach	77
Exploiting temporal aspects of cancer immunotherapy	77
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications	76
Context-dependent functions of pattern recognition receptors in cancer	75
Gasdermin E shields PDAC	71
Targeting the DNA damage response in immuno-oncology: developments and opportunities	69
Epigenomic heterogeneity as a source of tumour evolution	68
A guide to artificial intelligence for cancer researchers	67
Stem-like exhausted and memory CD8+ T cells in cancer	66
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	63
Systemic immunity in cancer	61
Identification of personalized cancer neoantigens with HANSolo	60
AR blockers augment melanoma treatment	60
Cholesterol-fuelled glioblastoma	55
Patient-derived organoids unveil sarcoma vulnerabilities	54
Resolving the spatial heterogeneity of cancer in 3D	53
Connie J. Eaves (1944–2024)	52
How medical anthropology can contribute to cancer research	52
Eliminating false positives	50
Histological transformation to small-cell carcinoma	48
IgA strikes twice in ovarian cancer	47
Microbiota links to immunotherapy toxicity	47
Metastases arrive at other organs via bone	47
Addicted to extra chromosomes	47
Studying extrachromosomal DNA with the ecTag method	44
Bidirectional CART.BiTE cells bring new hope	44
Targeting transcription cycles in cancer	44
Advancing targeted protein degradation for cancer therapy	43
Let’s get critical: bringing Critical Race Theory into cancer research	39
Epithelial and stromal co-evolution and complicity in pancreatic cancer	38
The dynamic role of platelets in cancer progression and their therapeutic implications	37
Tertiary lymphoid structures as hubs of antitumour immunity	36
Epigenetic memory	34
Mapping the prostate cell family tree	34
Lighting up cancer initiation with mutant p53 reporters	33
Discovering new drivers of cancer aneuploidy	33
Differentiating high-grade neuroendocrine neoplasms	31
Catastrophic conformity	31
Transfer RNAs as dynamic and critical regulators of cancer progression	31
AT1 cells appear centre stage	30
Global post-mortem tissue donation programmes to accelerate cancer research	29
Impaired RNA clearance	29